Mycobacterium tuberculosis

Size: px
Start display at page:

Download "Mycobacterium tuberculosis"

Transcription

1 Mycobacterium tuberculosis

2 Mycobacterium tuberculosis Ø small, aerobic, nonmotile bacteria Ø Gram-positive bacillus Ø can survive in a dry state for weeks Ø grow only within the cells of a host organism Ø can be cultured in the laboratory

3 Mycobacterium tuberculosis Ø spread through the air Ø typically attack the lungs, but TB bacteria can attack any part of the body such as kidney, spine & brain Ø most infections are asymptomatic and latent Ø in latent infections eventually progress to active disease Ø the classic symptoms of active TB infection are a chronic cough with blood-tinged sputum, fever, night sweats & weight loss

4 Diagnosis Active TB: radiology (x-ray), PCR, microscopic examination, microbiological culture of body fluid M. Tuberculosis (stained red) in sputum Latent TB: skin test and/or blood test

5 Tuberculosis (TB) Ø /3 of the world s population is thought to have been infected with TB Ø 3.7 million chronic active cases globally in 27 Ø in 2, there were an estimated 8.8 million new cases &.5 million associated deaths, mostly occurring in developing countries Ø no. of TB cases has been decreasing since 26, and new cases have decreased since 22 Ø distribution of TB: 8%: in Asian & Africa Ø 5-% of the US population tested positive

6 Treatment If not treated properly, TB disease can be fatal latent TB infection treatment Regimens Drugs Duration Isoniazid 9 months Isoniazid 6 months Isoniazid & Rifapentine Rifampin Interval Daily Twice weekly Daily Twice weekly Minimum doses months Once weekly 2 4 months Daily 2

7 Treatment active TB disease treatment regimens Preferred Regimen Initial Phase Alternative Regimen Alternative Regimen Initial Phase Initial Phase Daily INH, RIF, PZA, and EMB* for Thrice- weekly INH, RIF, Daily INH, RIF, PZA, and EMB* 4 doses (2 weeks), then twice PZA, and EMB* for 24 for 56 doses (8 weeks) weekly for 2 doses (6 weeks) doses (8 weeks) Continuation Phase Continuation Phase Continuation Phase Thrice- weekly INH and Daily INH and RIF for 26 Twice- weekly INH and RIF for 36 RIF for 54 doses (8 doses (8 weeks) doses (8 weeks) weeks) or Twice- weekly INH and RIF for 36 doses (8 weeks) INH: isoniazid RIF: rifampin EMB: ethambutol PZA: pyrazinamide

8 Vaccination BCG (Bacille Calmette-Guérin) Ø often given to infants & small children in countries where TB is common Ø not widely used in US Ø should only be considered for children who have a negative TB skin test

9 organism chrosome size (Mb) %GC Gene Protein 394 Mycobacterium tuberculosis F ,998 Mycobacterium tuberculosis H37Rv ,62 43 Mycobacterium tuberculosis CCDC , Mycobacterium tuberculosis CCDC , Mycobacterium tuberculosis CDC , Mycobacterium tuberculosis CTRI , 3944 Mycobacterium tuberculosis H37Ra , Mycobacterium tuberculosis H37Rv ,7 4 Mycobacterium tuberculosis KZN ,7 459 Mycobacterium tuberculosis KZN , TotalB as es : S tdeva T C ontigc ount P er.unknowns P er.l arges ts eq Myc obac terium tuberc ulos is H37R v NC _ Myc obac terium tuberc ulos is C C DC 579 NC _ Myc obac terium tuberc ulos is C C DC 58 NC _ Myc obac terium tuberc ulos is C DC 55 NC _ Myc obac terium tuberc ulos is C TR I- 2 NC _ Myc obac terium tuberc ulos is F NC _ Myc obac terium tuberc ulos is H37R a NC _ Myc obac terium tuberc ulos is H37R v NC _ Myc obac terium tuberc ulos is K ZN435 NC _ Myc obac terium tuberc ulos is K ZN427 NC _

10 M. tuberculosis CCDC579 Genome Atlas

11 replic on of c hros omes # of rr NA operons Myc obac terium tuberc ulos is H37R v NC _962 Myc obac terium tuberc ulos is C C DC 579 NC _7523 Myc obac terium tuberc ulos is C C DC 58 NC _7522 Myc obac terium tuberc ulos is C DC 55 NC _2755 Myc obac terium tuberc ulos is C TR I- 2 NC _7524 Myc obac terium tuberc ulos is F NC _9565 Myc obac terium tuberc ulos is H37R a NC _9525 Myc obac terium tuberc ulos is H37R v NC _843 Myc obac terium tuberc ulos is K ZN435 NC _2943 Myc obac terium tuberc ulos is K ZN427 NC _6768

12 Phylogenetic tree from 6S rrna alignment Myc obac terium tuberc ulos is F NC _9565 Myc obac terium tuberc ulos is H37R v NC _843 Myc obac terium tuberc ulos is C C DC 579 NC _7523 Myc obac terium tuberc ulos is K ZN427 NC _6768 Myc obac terium tuberc ulos is C DC 55 NC _2755 Myc obac terium tuberc ulos is C TR I- 2 NC _7524 Myc obac terium tuberc ulos is C C DC 58 NC _7522 Myc obac terium tuberc ulos is K ZN435 NC _2943 Myc obac terium tuberc ulos is H37R a NC _9525 Myc obac terium tuberc ulos is H37R v NC _962

13 Alignment result for 6S rrna (52 bp)

14

15 % A T % G C Myc obac terium tuberc ulos is H37R v NC _ % 65.6% Myc obac terium tuberc ulos is C C DC 579 NC _ % 65.6% Myc obac terium tuberc ulos is C C DC 58 NC _ % 65.59% Myc obac terium tuberc ulos is C DC 55 NC _ % 65.6% Myc obac terium tuberc ulos is C TR I- 2 NC _ % 65.6% Myc obac terium tuberc ulos is F NC _ % 65.62% Myc obac terium tuberc ulos is H37R a NC _ % 65.6% Myc obac terium tuberc ulos is H37R v NC _ % 65.62% Myc obac terium tuberc ulos is K ZN435 NC _ % 65.6% Myc obac terium tuberc ulos is K ZN427 NC _ % 65.6%

16 M. tuberculosis CCDC579 Amino acid & codon usage

17 # gene predic ted # gene in gbk Myc obac terium tuberc ulos is H37R v NC _ Myc obac terium tuberc ulos is C C DC 579 NC _ Myc obac terium tuberc ulos is C C DC 58 NC _ Myc obac terium tuberc ulos is C DC 55 NC _ Myc obac terium tuberc ulos is C TR I- 2 NC _ Myc obac terium tuberc ulos is F NC _ Myc obac terium tuberc ulos is H37R a NC _ Myc obac terium tuberc ulos is H37R v NC _ Myc obac terium tuberc ulos is K ZN435 NC _ Myc obac terium tuberc ulos is K ZN427 NC _

18 Blast Matrix

19 Blast Atlas F CDC55 H37Rv_962 H37Rv_843 CTRI-2 CCDC579 CCDC58 KZN427 KZN435

20 Pancore plot orgsnism Mycobacterium tuberculosis H37Rv 2 Mycobacterium tuberculosis CDC55 TotalBases gene NC_ NC_ Mycobacterium tuberculosis H37Ra 4 Mycobacterium tuberculosis F NC_ NC_ Mycobacterium tuberculosis KZN435 6 Mycobacterium tuberculosis KZN427 NC_ NC_ Mycobacterium tuberculosis CCDC58 8 Mycobacterium tuberculosis CCDC579 9 Mycobacterium tuberculosis CTRI-2 NC_ Mycobacterium tuberculosis H37Rv NC_ NC_ NC_

21 PanGome Tree Mycobacterium tuberculosis CCDC58 NC_7522 Mycobacterium tuberculosis CCDC579 NC_7523 Mycobacterium tuberculosis KZN427 NC_6768 Mycobacterium tuberculosis KZN435 NC_2943 Mycobacterium tuberculosis CTRI-2 NC_7524 Mycobacterium tuberculosis F NC_9565 Mycobacterium tuberculosis H37Rv NC_962 Mycobacterium tuberculosis H37Rv NC_843 Mycobacterium tuberculosis H37Ra NC_9525 Mycobacterium tuberculosis CDC55 NC_2755

Mycobacterium tuberculosis

Mycobacterium tuberculosis Mycobacterium tuberculosis Mycobacterium tuberculosis Ø aerobic Gram-positive bacillus Ø grow in the cell of host organism Ø the pathogen causes tuberculosis Ø asymptomatic and latent infections Ø can

More information

Characteristics of Mycobacterium

Characteristics of Mycobacterium Mycobacterium Characteristics of Mycobacterium Very thin, rod shape. Culture: Aerobic, need high levels of oxygen to grow. Very slow in grow compared to other bacteria (colonies may be visible in up to

More information

Tuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats

Tuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats Tuberculosis Facts Below are frequently asked questions about TB, and their answers. If you have additional questions you may contact the City of Ennis Department of Health Services at 972-875-1234 or

More information

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY CHAPTER:1 TUBERCULOSIS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY GLOBAL EMERGENCY: * Tuberculosis kills 5,000 people a day! * 2.3 million die each year!

More information

Fundamentals of Tuberculosis (TB)

Fundamentals of Tuberculosis (TB) TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported

More information

Tuberculosis (TB) Fundamentals for School Nurses

Tuberculosis (TB) Fundamentals for School Nurses Tuberculosis (TB) Fundamentals for School Nurses June 9, 2015 Kristin Gall, RN, MSN/Pat Infield, RN-TB Program Manager Marsha Carlson, RN, BSN Two Rivers Public Health Department Nebraska Department of

More information

Tuberculosis Tools: A Clinical Update

Tuberculosis Tools: A Clinical Update Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary

More information

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

TUBERCULOSIS. Presented By: Public Health Madison & Dane County TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any

More information

Treatment of Tuberculosis, 2017

Treatment of Tuberculosis, 2017 Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,

More information

Diagnosis and Treatment of Tuberculosis, 2011

Diagnosis and Treatment of Tuberculosis, 2011 Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is

More information

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population

More information

Descriptive Epidemiology Project: Tuberculosis in the. United States. MPH 510: Applied Epidemiology. Summer A 2014

Descriptive Epidemiology Project: Tuberculosis in the. United States. MPH 510: Applied Epidemiology. Summer A 2014 Descriptive Epidemiology Project: Tuberculosis in the United States MPH 510: Applied Epidemiology Summer A 2014 June 1, 2014 1 The white plague affected thousands upon thousands of people in the 18 th

More information

Questions and Answers About

Questions and Answers About Questions and Answers About TB 2005 DEPARTMENT OF HEALTH AND HUMAN SERVICES TB Elimination Questions and Answers About TB 2005 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with

More information

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis

More information

Symptoms Latent TB Active TB

Symptoms Latent TB Active TB 1 Tuberculosis Tuberculosis (TB) is a disease that can spread through the air. It is caused by a bacterium called Mycobacterium tuberculosis. It usually affect the lungs. However, it can also affect other

More information

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN

More information

Northwestern Polytechnic University

Northwestern Polytechnic University Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions

More information

TB the basics. (Dr) Margaret (DHA) and John (INZ)

TB the basics. (Dr) Margaret (DHA) and John (INZ) TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2

More information

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures

More information

Questions and Answers About

Questions and Answers About Questions and Answers About TB 2002 DEPARTMENT OF HEALTH AND HUMAN SERVICES n Questions and Answers About TB 2002 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National

More information

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012 TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release

More information

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis? Tuberculosis Understanding, Investigating, Eliminating Jeff Maupin, RN Tuberculosis Control Nurse Sedgwick County Division of Health Objectives At the conclusion of this presentation, you will be able

More information

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 7 References Related ACA Standards 4 th Edition Standards for Adult Correctional Institutions 4-4350, 4-4355 These guidelines are based on the recommendations of the American Thoracic Society

More information

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.

More information

Evaluation of Mycobacterium tuberculosis specific T cell response to ESAT-6 and PPD antigen with ELISPOT assay

Evaluation of Mycobacterium tuberculosis specific T cell response to ESAT-6 and PPD antigen with ELISPOT assay In the name of God Evaluation of Mycobacterium tuberculosis specific T cell response to ESAT-6 and PPD antigen with ELISPOT assay presented by: M. Taheri Symptoms of TB Cough for more than two week Bloody

More information

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014 What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks

More information

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed

More information

Cooperation. Tuberculosis Panel on Tips from the Field. Introductions. Katie Dickerson, RN. David Miller, RN. Moni Muraki

Cooperation. Tuberculosis Panel on Tips from the Field. Introductions. Katie Dickerson, RN. David Miller, RN. Moni Muraki Tuberculosis Panel on Tips from the Field Lana Kay Tyer, RN MSN TB Nurse Consultant Department of Health Introductions Katie Dickerson, RN David Miller, RN Moni Muraki Cooperation 1 COOPERATION Long-term

More information

What Is TB? 388 How TB Is Spread 388 How to Know if a Person Has TB 389 How to Treat TB 389 Resistance to TB medicines 390

What Is TB? 388 How TB Is Spread 388 How to Know if a Person Has TB 389 How to Treat TB 389 Resistance to TB medicines 390 386 Chapter 25 In this chapter: What Is TB? 388 How TB Is Spread 388 How to Know if a Person Has TB 389 How to Treat TB 389 Resistance to TB medicines 390 Preventing TB 391 Working for Change 391 387 (TB)

More information

TUBERCULOSIS. What you need to know BECAUSE...CARING COMES NATURALLY TO US

TUBERCULOSIS. What you need to know BECAUSE...CARING COMES NATURALLY TO US TUBERCULOSIS What you need to know BECAUSE...CARING COMES NATURALLY TO US Are certain people more at risk of developing Tuberculosis Yes, while everyone exposed to the disease could develop TB, the following

More information

Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)

Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) CURTIS FOWLER MPT,PA C ASSISTANT CLINICAL PROFESSOR UNIVERSITY OF THE PACIFIC Learning objectives Recognize the appropriate

More information

Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015

Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Initiation Phase Part 1 Ginny Dowell, RN, BSN February 4, 2015 Ginny Dowell RN, BSN has the following disclosures to make:

More information

Mycobacterium tuberculosis. Lecture (14) Dr.Baha, AL-Amiedi Ph. D.Microbiology

Mycobacterium tuberculosis. Lecture (14) Dr.Baha, AL-Amiedi Ph. D.Microbiology Mycobacterium tuberculosis Lecture (14) Dr.Baha, AL-Amiedi Ph. D.Microbiology Robert Koch 1843-1910 German physician Became famous for isolating the anthrax bacillus (1877), tuberculosis bacillus (1882)

More information

Latent Tuberculosis Best Practices

Latent Tuberculosis Best Practices Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States

More information

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016 Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the

More information

Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018

Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018 Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018 1 Introduction This position paper replaces the 2004 WHO position paper on Bacille Calmette-Guérin (BCG) vaccine and the 2007 WHO

More information

Research in Tuberculosis: Translation into Practice

Research in Tuberculosis: Translation into Practice Case History Research in Tuberculosis: Translation into Practice This is a 6-year6 year-old Bosnian male, who presented to ER with one-week history of fever and occasional vomiting. No cough, difficulty

More information

Running head: TUBERCULOSIS 1

Running head: TUBERCULOSIS 1 Running head: TUBERCULOSIS 1 Tuberculosis Erin Burdi Ferris State University TUBERCULOSIS 2 Abstract Tuberculosis is one of the world s oldest infectious diseases. It is a disease that continues to affect

More information

Please distribute a copy of this information to each provider in your organization.

Please distribute a copy of this information to each provider in your organization. HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to

More information

Contact Investigation and Prevention in the USA

Contact Investigation and Prevention in the USA Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis

More information

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries

More information

Tuberculosis Populations at Risk

Tuberculosis Populations at Risk Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading

More information

TB BASICS: PRIORITIES AND CLASSIFICATIONS

TB BASICS: PRIORITIES AND CLASSIFICATIONS TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE NOVEMBER 1-4, 2016 TB BASICS: PRIORITIES AND CLASSIFICATIONS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1.

More information

An Investigation into Tuberculosis Control in India. Disa Linden-Perlis, Karin Wickman, Saya Kato & Ebony Blanch

An Investigation into Tuberculosis Control in India. Disa Linden-Perlis, Karin Wickman, Saya Kato & Ebony Blanch An Investigation into Tuberculosis Control in India Disa Linden-Perlis, Karin Wickman, Saya Kato & Ebony Blanch Mycobacterium tuberculosis Taken from Max Planck Institute for Infection Biology /Volker

More information

Diagnosis of drug resistant TB

Diagnosis of drug resistant TB Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million

More information

Photo : Sylvie Ricard. The state of TB in Nunavik

Photo : Sylvie Ricard. The state of TB in Nunavik Photo : Sylvie Ricard The state of TB in Nunavik 1 TB in Nunavik: an overview o What is TB? o What is the history of TB in the region? o What are the recent numbers? o Why are the numbers so high again?

More information

Proposed Regs.pdf

Proposed Regs.pdf Kansas Wesleyan University TB testing Policy In Compliance with Kansas Statue KSA 2009 Supp. 65-129, all Kansas Wesleyan University students who have traveled, resided in for more than three months, or

More information

Treatment of Latent TB Infection (LTBI)

Treatment of Latent TB Infection (LTBI) Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious

More information

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology

More information

Diagnosis and Medical Management of Latent TB Infection

Diagnosis and Medical Management of Latent TB Infection Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,

More information

The treatment of patients with initial isoniazid resistance

The treatment of patients with initial isoniazid resistance The treatment of patients with initial isoniazid resistance 2011 INTERTB Meeting, St George s, London Patrick Phillips, MRC Clinical Trials Unit DA Mitchison, AJ Nunn. 21 st October 2011 Outline Background

More information

Chapter 22. Pulmonary Infections

Chapter 22. Pulmonary Infections Chapter 22 Pulmonary Infections Objectives State the incidence of pneumonia in the United States and its economic impact. Discuss the current classification scheme for pneumonia and be able to define hospital-acquired

More information

TB BASICS: PRIORITIES AND CLASSIFICATIONS

TB BASICS: PRIORITIES AND CLASSIFICATIONS TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE MAY 8-11, 2018 TB BASICS: PRIORITIES AND CLASSIFICATIONS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. List

More information

Analysis. Answers. Action. Saturday Night Fever. Shaka Brown Capital Congress

Analysis. Answers. Action.   Saturday Night Fever. Shaka Brown Capital Congress Saturday Night Fever Shaka Brown Capital Congress Shaka Zulu October 31, 2012 SICK SUCKS How my illness started October 2013 August to October 2013 Symptoms: Severe fatigue Night sweats Low grade fever

More information

#114 - Tuberculosis Update [1]

#114 - Tuberculosis Update [1] Published on Excellence In Learning (https://excellenceinlearning.net) Home > #114 - Tuberculosis Update #114 - Tuberculosis Update [1] Please login [2] or register [3] to take this course. $8.00 Course

More information

What is tuberculosis? What causes tuberculosis?

What is tuberculosis? What causes tuberculosis? What is tuberculosis? What causes tuberculosis? Last updated: Thursday 4 September 2014 Tuberculosis Infectious Diseases / Bacteria / Viruses Respiratory / Asthma Some may see Tuberculosis as a historical

More information

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin

More information

Communicable Disease Control Manual Chapter 4: Tuberculosis

Communicable Disease Control Manual Chapter 4: Tuberculosis Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict

More information

11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016

11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016 Disclosures Update In Tuberculosis, Indiana 2017 Bradley Allen, MD, PhD, FACP, FIDSA Indiana University School of Medicine Division of Infectious Diseases Roudebush VAMC Indianapolis Medical Consultant,

More information

Tuberculosis: A Provider s Guide to

Tuberculosis: A Provider s Guide to Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency

More information

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.

More information

LESSON ASSIGNMENT. After completing this lesson, you should be able to:

LESSON ASSIGNMENT. After completing this lesson, you should be able to: LESSON ASSIGNMENT LESSON 6 Tuberculosis. TEXT ASSIGNMENT Paragraphs 6-1 through 6-11. LESSON OBJECTIVES After completing this lesson, you should be able to: 6-1. Identify the characteristics, signs/ symptoms,

More information

Medical Bacteriology- Lecture 10. Mycobacterium. Actinomycetes. Nocardia

Medical Bacteriology- Lecture 10. Mycobacterium. Actinomycetes. Nocardia Medical Bacteriology- Lecture 10 Mycobacterium Actinomycetes Nocardia 1 Mycobacterium Characteristics - Large, very weakly gram positive rods - Obligate aerobes, related to Actinomycetes - Catalase positive

More information

Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore

Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis

More information

Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation

Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation Randall Reves, MD, MSc TB Consultant Professor of Medicine and

More information

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict

More information

Michael J. Huey, MD. NYSCHA Annual Meeting WE-2, October 19, 2016

Michael J. Huey, MD. NYSCHA Annual Meeting WE-2, October 19, 2016 Michael J. Huey, MD Assistant Vice President and Executive Director Emory University Student Health Services Associate Professor, Family and Preventive Medicine Emory University School of Medicine President-elect

More information

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey

More information

TB in Corrections Phoenix, Arizona

TB in Corrections Phoenix, Arizona TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests

More information

TUBERCULOSIS. Famous victims in their intellectual prime: Chopin, Paganini, Thoreau, Keats, Elizabeth Browning, Brontës

TUBERCULOSIS. Famous victims in their intellectual prime: Chopin, Paganini, Thoreau, Keats, Elizabeth Browning, Brontës TUBERCULOSIS GENERAL Tuberculosis (TB) kills 1,700,000 annually worldwide. "The Captain of all the men of death that came to take him away was the consumption, for it was that which brought him down to

More information

Transmissibility, virulence and fitness of resistant strains of M. tuberculosis. CHIANG Chen-Yuan MD, MPH, DrPhilos

Transmissibility, virulence and fitness of resistant strains of M. tuberculosis. CHIANG Chen-Yuan MD, MPH, DrPhilos Transmissibility, virulence and fitness of resistant strains of M. tuberculosis CHIANG Chen-Yuan MD, MPH, DrPhilos Transmissibility, Virulence and Fitness of resistant strains of M. tuberculosis For infectious

More information

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE) TB IN EMERGENCIES Department of Epidemic and Pandemic Alert and Response (EPR) Health Security and Environment Cluster (HSE) (Acknowledgements WHO Stop TB Programme WHO/STB) 1 Why TB? >33% of the global

More information

Primer on Tuberculosis (TB) in the United States

Primer on Tuberculosis (TB) in the United States Primer on Tuberculosis (TB) in the United States The purpose of this primer is to provide instructors who have no prior background in TB research or clinical care with basic knowledge that they may find

More information

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe

More information

MO TASEM AJ Nader Alaridah

MO TASEM AJ Nader Alaridah 22 MO TASEM AJ...... Nader Alaridah Mycobacterium ** Mycobacterium is a class of Actinobacteria, which are non-spore forming, non-motile and acid-fast bacilli ( they remain stained with the red dye carbofuchsin

More information

PEDIATRIC TB. Modified PPT from group A seminar (F)

PEDIATRIC TB. Modified PPT from group A seminar (F) PEDIATRIC TB Modified PPT from group A seminar (F) objectives the epidemiology of pediatric TB. TB Mycobacteriology. pediatric TB presentations compared to adults TB. Know the differences between, and

More information

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea

More information

Tuberculosis: A Persistent Threat to Public Health. A Publication of the HCH Clinicians Network

Tuberculosis: A Persistent Threat to Public Health. A Publication of the HCH Clinicians Network Vol. 18, No. 1 Winter 2014 A Publication of the HCH Clinicians Network San Francisco TB Clinic Medical Director, Dr. Chris Keh reads a Tuberculin Skin Test (TST). Tuberculosis: A Persistent Threat to Public

More information

Laboratory Diagnosis for MDR TB

Laboratory Diagnosis for MDR TB Laboratory Diagnosis for MDR TB Neha Shah MD MPH Centers for Disease Control and Prevention Division of Tuberculosis Elimination California Department of Public Health Guam March 07 Objectives Describe

More information

Tuberculosis Education for the Medical Professional

Tuberculosis Education for the Medical Professional Tuberculosis Education for the Medical Professional North Dakota Diagnosis and Medical Management of Latent TB Infection Dawn Farrell, RN, BSN, PHN Maria Robles, BSN July 10, 2007 Tuberculosis Education

More information

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Who Should Be Screened for Latent Tuberculosis Infection (LTBI)?... 2 What tests are used to screen for LTBI?... 2 How

More information

Tuberculosis: update 2013

Tuberculosis: update 2013 Tuberculosis: update 2013 William R. Bishai, MD, PhD Center for TB Research Division of Infectious Diseases Department of Medicine Johns Hopkins School of Medicine Question 1 A TB speaker at a major conference

More information

MYCOBACTERIUM. Mycobacterium Tuberculosis (Mtb) nontuberculous mycobacteria (NTM) Mycobacterium lepray

MYCOBACTERIUM. Mycobacterium Tuberculosis (Mtb) nontuberculous mycobacteria (NTM) Mycobacterium lepray MYCOBACTERIUM nontuberculous mycobacteria (NTM) Mycobacterium Tuberculosis (Mtb) Mycobacterium lepray 1-tubercle bacilli are thin 2- straight rods 3- obligate aerobes 4- derive energy from the oxidation

More information

New Entrant Screening and Latent TB Get screened and find out if you have TB infection before you develop TB disease!

New Entrant Screening and Latent TB Get screened and find out if you have TB infection before you develop TB disease! New Entrant Screening and Latent TB Get screened and find out if you have TB infection before you develop TB disease! Screening and treatment for TB are free. What does this leaflet cover? What is Tuberculosis

More information

NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY

NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY Neil W. Schluger, M.D. Professor of Medicine, Epidemiology and Environmental Health Sciences Columbia University Global tuberculosis incidence

More information

Chapter 08 Lecture Outline

Chapter 08 Lecture Outline Chapter 08 Lecture Outline See separate PowerPoint slides for all figures and tables preinserted into PowerPoint without notes. Copyright 2016 McGraw-Hill Education. Permission required for reproduction

More information

Qian Gao Fudan University

Qian Gao Fudan University Qian Gao Fudan University Outline Background & Objectives Genotyping methods Establish the epidemiological field sites Preliminary results of Molecular epidemiology of TB in China Molecular epidemiology

More information

TB and Comorbidities Adriana Vasquez, MD April 12, 2018

TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:

More information

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening

More information

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis? Biology Report Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis? Introduction Tuberculosis is a serious disease caused by the bacterium Mycobacterium

More information

Treatment of Tuberculosis

Treatment of Tuberculosis TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features

More information

Chapter 5 Treatment for Latent Tuberculosis Infection

Chapter 5 Treatment for Latent Tuberculosis Infection Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI

More information

Application of New Diagnostics and Preventative Treatment in Low and High Burden Settings

Application of New Diagnostics and Preventative Treatment in Low and High Burden Settings Application of New Diagnostics and Preventative Treatment in Low and High Burden Settings Edward Nardell, MD Brigham & Women s Hospital Harvard Medical School Partners In Health Disclosures opps! Served

More information